NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

380.05 5.60 (1.50%)

30.60% Gain from 52W Low

7.0M NSE+BSE Volume

NSE 04 Jul, 2025 3:31 PM (IST)

50,811.3

Market Cap

Market Leader

1.2

Beta 1Year

High Volatility

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Biocon Ltd.

16 Nov 2022

380.05

1.50%

Growth across segments

Buy: Biocon Ltd.

Recommendation Target

ICICI Securities Limited

Biocon Limited’s (Biocon) Q2FY23 performance was ahead of our estimates led by
better than expected results in the generics and research services. Generics revenue was up 17.5% YoY to Rs6.2bn while Research services delivered a robust growth of 25.9% YoY to Rs.7.7bn.

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

15 Nov 2022

380.05

1.50%

Biocon

Hold: Biocon Ltd.

Target

ICICI Direct

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

15 Nov 2022

380.05

1.50%

Result Update:Biocon

Hold: Biocon Ltd.

Recommendation Target

Axis Direct

Management indicated that R&D costs will increase in the upcoming quarters which may pose threat to the current margins of the company. We, therefore, recommend a HOLD rating on the stock with a TP of Rs 310/share.

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

10 Aug 2022

380.05

1.50%

BIOCON LTD

Hold: Biocon Ltd.

Recommendation Target

Geojit BNP Paribas

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

28 Jul 2022

380.05

1.50%

Biocon

Hold: Biocon Ltd.

Target

ICICI Direct

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

30 Apr 2022

380.05

1.50%

Biocon

Hold: Biocon Ltd.

ICICI Direct

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

29 Apr 2022

380.05

1.50%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We recommend a BUY rating on the stock with a Target Price of Rs 420.

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon Ltd.

04 Mar 2022

380.05

1.50%

Biocon

Hold: Biocon Ltd.

Target

ICICI Securities Limited

Biosimilar US pipeline: (approvals - Pegfilgrastim, Trastuzumab, Glargine, Adalimumab); filed - Aspart and Bevacizumab Revenue breakup FY21: biosimilars (37%), generics (31%), CRAMS (29%)...

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

28 Feb 2022

380.05

1.50%

Biosimilar deal with Viatris completes the value chain in its Biologics business

Neutral: Biocon Ltd.

Target

Motilal Oswal

BBL (a subsidiary of BIOS) will acquire Viatris' Biosimilar business to create a vertically integrated company in the Biologics segment. With this acquisition, BBL will acquire the commercial infrastructure in developed/emerging markets, rights for all Biosimilar assets (including the in-licensed portfolio), and the option to acquire rights of bAflibercept. This also fills BBL's gap in regulatory development and supply chain management of Biosimilars in the developed market. The management pegs the estimated revenue/EBITDA of Viatris'...

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Is Biocon Ltd. worth buying?

721 Votes:

Buy 75.03%

Sell 16.23%

Hold 8.74%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf